The 2026 mid-year reporting season has arrived, and Chinese innovative drug companies are accelerating their commercialization pace, with broadly positive earnings expectations for the sector. Several leading enterprises that have disclosed results or pre-announcements have reported strong financial figures. Driven by these better-than-expected earnings from major players, the innovation drug sector has shown broad strength recently, attracting capital toward high-quality assets with proven commercialization capabilities, clear overseas expansion prospects, and solid industry trends.

The on-exchange T+0-capable Huatai-PineBridge Hang Seng Innovation Drug ETF (520500) has seen average daily trading volume reach 2.34 billion yuan since July, a significant jump in capital activity compared to the 881 million yuan average daily turnover in the first half of 2026. Amid robust trading, the ETF's latest shares outstanding and fund size reached 2.212 billion units and 3.219 billion yuan respectively as of August 10. Year-to-date, the product's shares have increased by 76.68%, and its size has grown by 66.1%.

On the earnings front, several domestic leading pharmaceutical companies that have released results or pre-announcements have delivered half-year reports that exceeded expectations. Many have not only achieved impressive profit growth but have also raised their full-year revenue guidance or significantly increased their annual revenue forecasts, confirming the recovery in supply chain orders. Overall, the innovation drug sector is currently in a critical window for fundamental validation. As mid-year reports are continuously released, quality assets with solid earnings support and growth logic are likely to attract further attention.

From an overseas perspective, numerous global multinational pharmaceutical companies have recently submitted their mid-year results, with several MNC leaders performing strongly. The global innovation drug industry chain is experiencing rising prosperity, with popular segments like the GLP-1 weight loss market acting as a core driver for these earnings surprises, as multiple products see high sales growth. The strong performance of MNCs suggests a solid foundation for key links in the global innovation drug supply chain. The robust earnings growth and sustained R&D investment from leading pharmaceutical companies set the stage for the prosperity to flow through the entire industry chain.

A recent research report from Zhongtai Securities stated that since 2026, China's innovation drug industry has gradually entered a phase of value realization. The industry's logic has shifted from relying on BD event catalysts to overseas commercialization, clinical data validation, and sustained revenue contributions. Recent financial reports from leading overseas pharmaceutical companies are continuously validating the value of Chinese innovative assets, with MNCs strategically upgrading their positioning of Chinese innovation drugs. The ongoing commercialization validation both domestically and internationally is strengthening market confidence. The report recommends focusing on three main themes: "earnings realization + global innovation + industry cycle."

It is noted that the on-exchange T+0-capable Huatai-PineBridge Hang Seng Innovation Drug ETF (520500), which tracks the Hang Seng Innovation Drug Index, invests in 40 leading Hong Kong-listed innovative drug companies through the QDII mechanism. The index primarily focuses on mid-to-upstream segments of the innovation drug field, including biopharmaceuticals, chemical pharmaceuticals, and active pharmaceutical ingredients (APIs), bringing together a group of research-driven enterprises with strong R&D capabilities and development potential. Managed by Huatai-PineBridge Fund Management, one of China's first ETF managers with over 19 years of experience in index investing, the fund has created transparent, convenient, and low-cost index tools such as the CSI 300 ETF (510300) and the A500 ETF (563360). As of the end of June 2026, the company's ETFs had generated cumulative profits of over 180.6 billion yuan for holders in the past two years, making it one of only three public fund companies in the entire A-share market to accumulate over 160 billion yuan in profits during that period.